Avtor/Urednik		Letonja, Mitja
Naslov		Praktične izkušnje z valsartanom
Prevedeni naslov		Practical experience with valsartan
Tip		članek
Vir		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum Iz prakse za prakso z mednarodno udeležbo. 13. srečanje internistov in zdravnikov splošne medicine; 2002 maj 10-11; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2002
Obseg		str. 253-62
Jezik		slo
Abstrakt		There are theoretical reasons why blocking at the receptor level may be more effective in inhibiting the deleterious effect of angiotensin II than pharmacologicai inhibition of the conversion of angiotensin I to II. Angiotensin Il blockers block AT1 receptors. Angiotensin II blockers are effective and well tolerated in patients with hypertension. Large clinical trial Val-HeFT has confirmed that valsartan (angiotensin II blocker) significantly reduces combined mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. Whether valsartan has an important advantage in comparison with other drugs in the treatment of hypertension, diabetes mellitus and myocardial infarction will be confirmed or reversed by a large clinical trial: VALUE, VALIANT, ABCD-2-V.
Deskriptorji		HYPERTENSION RECEPTORS, ANGIOTENSIN ANGIOTENSIN-CONVERTING ENZYME INHIBITORS DIABETES MELLITUS MYOCARDIAL INFARCTION HEART FAILURE, CONGESTIVE